The company intends to preserve its existing commercial and medical affairs infrastructure, aiming to stabilize operations ahead of a crucial pre-supplemental Biologics License Application meeting with the Food and Drug Administration scheduled for August. Executives plan to follow this with a formal supplemental filing in the fourth quarter, hoping to bolster the market position of loncastuximab tesirine-lpyl.

Management anticipates these structural changes will generate annual savings of $10 million. To achieve this, the firm will incur a one-time, $3 million pretax charge covering severance and related transition expenses. Despite the disruption, internal projections suggest the company maintains sufficient cash reserves to fund operations through at least 2028.